In addition, suggestions were made in the severe asthma guidelines of GINA regarding preferred biologics for the type-2 high asthma phenotype, and it was emphasized that factors determining the response to treatment should be taken into consideration .1 Therapy should be initiated with anti-IL5/anti-IL5R mAbs in patients with severe uncontrolled asthma who have a blood eosinophil count of ≥300/μL. Here, IL5 is linked to asthma.